COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention

Igor Panashchuk; Oleksii Tatskyi; Sergii Konovalenko

doi:doi:10.11648/j.ajim.20210906.11

| Peer-Reviewed

COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention

Igor Panashchuk, Oleksii Tatskyi, Sergii Konovalenko

Published in American Journal of Internal Medicine (Volume 9, Issue 6)

Received: 22 July 2021 Accepted: 30 August 2021 Published: 10 November 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Chronic obstructive pulmonary disease (COPD) occurs due to chronic inflammation, which leads to thickening of the airway walls, increased mucus production and, ultimately, permanent changes in lung structure. Meta-analysis indicates an increased risk of lung cancer in patients with COPD, so timely and comprehensive cancer prevention is extremely important. Objective: Determine the mechanisms of interaction between immune peptides and immunocompetent cells, which lead to the elimination of pathogens and prevent the development of metaplasia on the background of chronic inflammation. Methods: Selection and analysis of open access scientific publications. Results: Restoring the ability of secretory cells to synthesize IgA and maintaining this synthesis at the appropriate level can provide the necessary protection of the respiratory system from infection. Strengthening immune surveillance over the mucous membrane promotes not only the elimination of pathogens, but also to the destruction and removal of disabled and infected cells and cells that have undergone metaplasia - this is how the immunity program is implemented to counteract infection and prevent cancer. Conclusion: The use of exogenous anti-infective peptides for the treatment and prevention of exacerbations of COPD in the context of antibiotic resistance, to stimulate airway immune function and to prevent cancer is currently considered a promising area in clinical pulmonology.

Published in	American Journal of Internal Medicine (Volume 9, Issue 6)
DOI	10.11648/j.ajim.20210906.11
Page(s)	248-252
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

COPD, Exacerbation, Antiinfective Peptides, Immune Correction, Lung Cancer Prevention

References

[1]	Yawn BP, Mintz ML, Doherty DE. GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2021; 16: 289-299.
[2]	Unninayar, Dana et al. “Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations.” International journal of chronic obstructive pulmonary disease vol. 16 545-552. 2 Mar. 2021.
[3]	Polosukhin VV, Cates JM, Lawson WE, et al. Bronchial secretory immunoglobulin A deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 184 (3): 317-327.
[4]	Ferrera MC, Labaki WW, Han MK. Advances in Chronic Obstructive Pulmonary Disease. Annu Rev Med. 2021 Jan 27; 72: 119-134.
[5]	Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2020 Mar 15; 201 (6): 671-680.
[6]	Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis, and management of chronic obstructive pulmonary disease; 2020. Available from: https://goldcopd.org. Accessed October26, 2020.
[7]	Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015; 385 (9971): 899–909.
[8]	Chilvers ER, Lomas DA. Diagnosing COPD in non-smokers: splitting not lumping. Thorax. 2010; 65 (6): 465–466.
[9]	Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021; 203 (1): 24-36.
[10]	Rodríguez-Roisin R. The airway pathophysiology of COPD: implications for treatment. COPD. 2005; 2 (2): 253–262.
[11]	Doherty DE. The pathophysiology of airway dysfunction. Am J Med. 2004; 117 (Suppl12A): 11–23.
[12]	Zhang X, Jiang N, Wang L, Liu H, He R. Chronic obstructive pulmonary disease and risk of lung cancer: a meta-analysis of prospective cohort studies. Oncotarget. 2017; 8 (44): 78044-78056.
[13]	Calverley PMA. COPD in the time of COVID-19. EClinical Medicine. 2021; 34: 100832.
[14]	Halpin DMG, Vogelmeier CF, Agusti AA. COPD & COVID-19. Arch Bronconeumol (Engl Ed). 2021; 57 (3): 162-164.
[15]	Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021; 33: 100789.
[16]	Cardoso P, Glossop H, Meikle TG, Aburto-Medina A, Conn CE, Sarojini V, Valery C. Molecular engineering of antimicrobial peptides: microbial targets, peptide motifs and translation opportunities. Biophys Rev. 2021 Jan 21: 1-35.
[17]	Divyashree M, Mani MK, Reddy D, et al. Clinical Applications of Antimicrobial Peptides (AMPs): Where do we Stand Now?. Protein Pept Lett. 2020; 27 (2): 120-134.
[18]	Huan Y, Kong Q, Mou H, Yi H. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front Microbiol. 2020; 11: 582779.
[19]	Patrulea V, Borchard G, Jordan O. An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections. Pharmaceutics. 2020; 12 (9): 840.
[20]	Fruitwala S, El-Naccache DW, Chang TL. Multifaceted immune functions of human defensins and underlying mechanisms. Semin Cell Dev Biol. 2019 Apr; 88: 163-172.
[21]	Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: Application informed by evolution. Science. 2020; 368 (6490): eaau 5480.
[22]	Chao YX, Rötzschke O, Tan EK. The role of IgA in COVID-19. Brain Behav Immun. 2020; 87: 182-183.
[23]	Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021; 13 (577): eabd 2223.
[24]	Lippi G, Mattiuzzi C. Clinical value of anti-SARS-COV-2 serum IgA titration in patients with COVID-19. J Med Virol. 2021; 93 (3): 1210-1211.
[25]	Beniuk V, Goncharenko V, Kurchenko A, Tatskyy O, Konovalenko S, Vintoniuk S, Melnikov S, Nurimanov K, Podpriatov S. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. International Journal of Immunology. Vol. 8, No. 1, 2020, 1-8.
[26]	Zakharenko N, Tatskiy O, Konovalenko S. Prospects for the Treatment of Endometriosis: The Effect of Immune Peptides on the Reactivation of Immune Surveillance over Ectopic Endometrial Cells. Journal of Gynecology and Obstetrics. Vol. 8, No. 5, 2020, 148-153.
[27]	Litvinenko O. O, Tatskiy O. F, Konovalenko V. F, et al. Breast Cancer Relapse Prevention: Role of Anti-Relapsing Immunocorrection. Cancer Sci Res. 2019; 2 (2); 1-6.
[28]	Shypulin V, Stoliarova O, Konovalenko V, Tatskyy O, Didenko G, Konovalenko S. Study of the Exogenous Peptide Effect on the TGF-β1 Expression-A Risk Factor for the Hepatocellular Carcinoma Recurrence. American Journal of Biomedical and Life Sciences. Vol. 7, No. 4, 2019, pp. 73-78.
[29]	Upert G, Luther A, Obrecht D, Ermert P. Emerging peptide antibiotics with therapeutic potential. Med Drug Discov. 2021; 9: 100078.
[30]	Parameswaran GI, Sethi S, Murphy TF. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest. 2011 Sep; 140 (3): 611-617.
[31]	Lecaille F, Lalmanach G, Andrault PM. Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases. Biochimie. 2016 Mar; 122: 151-68.
[32]	Seiler F, Lepper PM, Bals R, Beisswenger C. Regulation and function of antimicrobial peptides in immunity and diseases of the lung. Protein Pept Lett. 2014 Apr; 21 (4): 341-51.
[33]	Bals R, Hiemstra PS. Antimicrobial peptides in COPD-basic biology and therapeutic applications. Curr Drug Targets. 2006 Jun; 7 (6): 743-50.
[34]	Persson LJ, Aanerud M, Hardie JA, Miodini Nilsen R, Bakke PS, Eagan TM, Hiemstra PS. Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease. Eur Respir J. 2017 Mar 15; 49 (3): 1601328.
[35]	Hiemstra PS, Amatngalim GD, van der Does AM, Taube C. Antimicrobial Peptides and Innate Lung Defenses: Role in Infectious and Noninfectious Lung Diseases and Therapeutic Applications. Chest. 2016 Feb; 149 (2): 545-551.
[36]	Coya JM, Akinbi HT, Sáenz A, Yang L, Weaver TE, Casals C. Natural Anti-Infective Pulmonary Proteins: In Vivo Cooperative Action of Surfactant Protein SP-A and the Lung Antimicrobial Peptide SP-BN. J Immunol. 2015; 195 (4): 1628-1636.

Cite This Article

Plain Text BibTeX RIS

APA Style

Igor Panashchuk, Oleksii Tatskyi, Sergii Konovalenko. (2021). COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention. American Journal of Internal Medicine, 9(6), 248-252. https://doi.org/10.11648/j.ajim.20210906.11

Copy | Download

ACS Style

Igor Panashchuk; Oleksii Tatskyi; Sergii Konovalenko. COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention. Am. J. Intern. Med. 2021, 9(6), 248-252. doi: 10.11648/j.ajim.20210906.11

Copy | Download

AMA Style

Igor Panashchuk, Oleksii Tatskyi, Sergii Konovalenko. COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention. Am J Intern Med. 2021;9(6):248-252. doi: 10.11648/j.ajim.20210906.11

Copy | Download

@article{10.11648/j.ajim.20210906.11,
  author = {Igor Panashchuk and Oleksii Tatskyi and Sergii Konovalenko},
  title = {COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention},
  journal = {American Journal of Internal Medicine},
  volume = {9},
  number = {6},
  pages = {248-252},
  doi = {10.11648/j.ajim.20210906.11},
  url = {https://doi.org/10.11648/j.ajim.20210906.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210906.11},
  abstract = {Background: Chronic obstructive pulmonary disease (COPD) occurs due to chronic inflammation, which leads to thickening of the airway walls, increased mucus production and, ultimately, permanent changes in lung structure. Meta-analysis indicates an increased risk of lung cancer in patients with COPD, so timely and comprehensive cancer prevention is extremely important. Objective: Determine the mechanisms of interaction between immune peptides and immunocompetent cells, which lead to the elimination of pathogens and prevent the development of metaplasia on the background of chronic inflammation. Methods: Selection and analysis of open access scientific publications. Results: Restoring the ability of secretory cells to synthesize IgA and maintaining this synthesis at the appropriate level can provide the necessary protection of the respiratory system from infection. Strengthening immune surveillance over the mucous membrane promotes not only the elimination of pathogens, but also to the destruction and removal of disabled and infected cells and cells that have undergone metaplasia - this is how the immunity program is implemented to counteract infection and prevent cancer. Conclusion: The use of exogenous anti-infective peptides for the treatment and prevention of exacerbations of COPD in the context of antibiotic resistance, to stimulate airway immune function and to prevent cancer is currently considered a promising area in clinical pulmonology.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention
AU  - Igor Panashchuk
AU  - Oleksii Tatskyi
AU  - Sergii Konovalenko
Y1  - 2021/11/10
PY  - 2021
N1  - https://doi.org/10.11648/j.ajim.20210906.11
DO  - 10.11648/j.ajim.20210906.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 248
EP  - 252
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20210906.11
AB  - Background: Chronic obstructive pulmonary disease (COPD) occurs due to chronic inflammation, which leads to thickening of the airway walls, increased mucus production and, ultimately, permanent changes in lung structure. Meta-analysis indicates an increased risk of lung cancer in patients with COPD, so timely and comprehensive cancer prevention is extremely important. Objective: Determine the mechanisms of interaction between immune peptides and immunocompetent cells, which lead to the elimination of pathogens and prevent the development of metaplasia on the background of chronic inflammation. Methods: Selection and analysis of open access scientific publications. Results: Restoring the ability of secretory cells to synthesize IgA and maintaining this synthesis at the appropriate level can provide the necessary protection of the respiratory system from infection. Strengthening immune surveillance over the mucous membrane promotes not only the elimination of pathogens, but also to the destruction and removal of disabled and infected cells and cells that have undergone metaplasia - this is how the immunity program is implemented to counteract infection and prevent cancer. Conclusion: The use of exogenous anti-infective peptides for the treatment and prevention of exacerbations of COPD in the context of antibiotic resistance, to stimulate airway immune function and to prevent cancer is currently considered a promising area in clinical pulmonology.
VL  - 9
IS  - 6
ER  -

Copy | Download

Author Information

Igor Panashchuk

Department of Pulmonology and Evidence-Based Medicine, F. G. Yanovsky National Institute of Phthisiology and Pulmonology NAMS of Ukraine, Kyiv, Ukraine
Oleksii Tatskyi

Department of Immunology, International Biotherapy Institute, Kyiv, Ukraine
Sergii Konovalenko

Department of Immunology, International Biotherapy Institute, Kyiv, Ukraine

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Igor Panashchuk, Oleksii Tatskyi, Sergii Konovalenko. (2021). COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention. American Journal of Internal Medicine, 9(6), 248-252. https://doi.org/10.11648/j.ajim.20210906.11

Copy | Download

ACS Style

Igor Panashchuk; Oleksii Tatskyi; Sergii Konovalenko. COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention. Am. J. Intern. Med. 2021, 9(6), 248-252. doi: 10.11648/j.ajim.20210906.11

Copy | Download

AMA Style

Igor Panashchuk, Oleksii Tatskyi, Sergii Konovalenko. COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention. Am J Intern Med. 2021;9(6):248-252. doi: 10.11648/j.ajim.20210906.11

Copy | Download

@article{10.11648/j.ajim.20210906.11,
  author = {Igor Panashchuk and Oleksii Tatskyi and Sergii Konovalenko},
  title = {COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention},
  journal = {American Journal of Internal Medicine},
  volume = {9},
  number = {6},
  pages = {248-252},
  doi = {10.11648/j.ajim.20210906.11},
  url = {https://doi.org/10.11648/j.ajim.20210906.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210906.11},
  abstract = {Background: Chronic obstructive pulmonary disease (COPD) occurs due to chronic inflammation, which leads to thickening of the airway walls, increased mucus production and, ultimately, permanent changes in lung structure. Meta-analysis indicates an increased risk of lung cancer in patients with COPD, so timely and comprehensive cancer prevention is extremely important. Objective: Determine the mechanisms of interaction between immune peptides and immunocompetent cells, which lead to the elimination of pathogens and prevent the development of metaplasia on the background of chronic inflammation. Methods: Selection and analysis of open access scientific publications. Results: Restoring the ability of secretory cells to synthesize IgA and maintaining this synthesis at the appropriate level can provide the necessary protection of the respiratory system from infection. Strengthening immune surveillance over the mucous membrane promotes not only the elimination of pathogens, but also to the destruction and removal of disabled and infected cells and cells that have undergone metaplasia - this is how the immunity program is implemented to counteract infection and prevent cancer. Conclusion: The use of exogenous anti-infective peptides for the treatment and prevention of exacerbations of COPD in the context of antibiotic resistance, to stimulate airway immune function and to prevent cancer is currently considered a promising area in clinical pulmonology.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention
AU  - Igor Panashchuk
AU  - Oleksii Tatskyi
AU  - Sergii Konovalenko
Y1  - 2021/11/10
PY  - 2021
N1  - https://doi.org/10.11648/j.ajim.20210906.11
DO  - 10.11648/j.ajim.20210906.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 248
EP  - 252
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20210906.11
AB  - Background: Chronic obstructive pulmonary disease (COPD) occurs due to chronic inflammation, which leads to thickening of the airway walls, increased mucus production and, ultimately, permanent changes in lung structure. Meta-analysis indicates an increased risk of lung cancer in patients with COPD, so timely and comprehensive cancer prevention is extremely important. Objective: Determine the mechanisms of interaction between immune peptides and immunocompetent cells, which lead to the elimination of pathogens and prevent the development of metaplasia on the background of chronic inflammation. Methods: Selection and analysis of open access scientific publications. Results: Restoring the ability of secretory cells to synthesize IgA and maintaining this synthesis at the appropriate level can provide the necessary protection of the respiratory system from infection. Strengthening immune surveillance over the mucous membrane promotes not only the elimination of pathogens, but also to the destruction and removal of disabled and infected cells and cells that have undergone metaplasia - this is how the immunity program is implemented to counteract infection and prevent cancer. Conclusion: The use of exogenous anti-infective peptides for the treatment and prevention of exacerbations of COPD in the context of antibiotic resistance, to stimulate airway immune function and to prevent cancer is currently considered a promising area in clinical pulmonology.
VL  - 9
IS  - 6
ER  -

Copy | Download